CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)
South Korea flag South Korea · Delayed Price · Currency is KRW
569.00
+3.00 (0.53%)
Sep 18, 2026, 3:30 PM KST

CMG Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Net Income
4,640-10,0772,6956,455-388.143,051
Depreciation & Amortization
2,6853,0823,3462,5582,2842,106
Loss (Gain) From Sale of Assets
-41.61-10.2114.0922.76-0.5
Asset Writedown & Restructuring Costs
5,2055,1651,133241.9732991.25
Loss (Gain) From Sale of Investments
-3,180-1,0475,909-35.584,145-534.01
Loss (Gain) on Equity Investments
1,5551,3631,086-1,1343,807-
Stock-Based Compensation
17.3140.2257.0960.2926.64439.08
Provision & Write-off of Bad Debts
1,764954.46468.4310.6-219.54213.58
Other Operating Activities
-9,7384,449-5,0463,436-764.942,545
Change in Accounts Receivable
-11,009-4,357-8,212-2,864-1,463-3,185
Change in Inventory
5,712-6,987-4,677-497.72-8,857-939.47
Change in Accounts Payable
-2,992-2,4322,816-2,0496,207165.71
Change in Other Net Operating Assets
-5,340-1,164703.02-2,248-190.64-1,129
Operating Cash Flow
-10,723-11,020290.093,9384,9382,823
Operating Cash Flow Growth
---92.63%-20.24%74.88%218.39%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Capital Expenditures
-38,729-29,630-28,098-12,384-8,382-8,176
Sale of Property, Plant & Equipment
4080.94-1.5-0.5
Cash Acquisitions
----3,129--
Sale (Purchase) of Intangibles
-2,960-3,011-3,150-2,861-1,926-3,474
Investment in Securities
41,11546,449-2,616-16,8343,485-58,948
Other Investing Activities
-295-328.35164.73-45491.9
Investing Cash Flow
-828.3713,626-55,743-28,221-10,868-70,596

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Short-Term Debt Issued
-1,500----
Long-Term Debt Issued
--56,78521,5006,000-
Total Debt Issued
58,5001,50056,78521,5006,000-
Long-Term Debt Repaid
--246.87-294.31-404.51-371.85-113.56
Net Debt Issued (Repaid)
16,8001,25356,49121,0955,628-113.56
Issuance of Common Stock
-----72,992
Common Dividends Paid
----29.28--
Other Financing Activities
-20.37-307.34292.32-0-0-
Financing Cash Flow
16,779945.7956,78321,0665,62872,878

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Foreign Exchange Rate Adjustments
27.92-17.1815.123.07-0.940.44
Miscellaneous Cash Flow Adjustments
-0-0-00-
Net Cash Flow
5,2573,5351,346-3,213-303.225,106

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Free Cash Flow
-49,451-40,650-27,808-8,446-3,444-5,352
Free Cash Flow Growth
------
Free Cash Flow Margin
-42.74%-38.63%-28.06%-8.99%-4.19%-9.13%
Free Cash Flow Per Share
-334.58-281.84-51.60-60.81-24.80-44.03
Levered Free Cash Flow
-31,139-42,983-33,0241,460--10,906
Unlevered Free Cash Flow
-30,495-41,002-31,4541,509--10,900

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Cash Interest Paid
1,3701,049870.52457.46194.75-
Cash Income Tax Paid
518.71483.4141.22687.44107.61183.95
Change in Working Capital
-13,629-14,940-9,370-7,658-4,304-5,087